Cargando…

Phase 2b Study of an Ad26.RSV.preF Vaccine for Prevention of RSV-mediated Respiratory Tract Disease in Older Adults

Respiratory syncytial virus (RSV) may cause serious lower respiratory tract disease (LRTD) in older adults, and there is currently no licensed vaccine. CYPRESS (NCT03982199) is a randomized, double-blind, placebo-controlled Phase 2b proof-of-concept trial of an Ad26.RSV.preF-based vaccine for the pr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Falsey, Ann, Williams, Kristi, Gymnopoulou, Efi, Bart, Stephan, Ervin, John, De Paepe, Els, Comeaux, Christy, Heijnen, Esther
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8682535/ http://dx.doi.org/10.1093/geroni/igab046.3723

Ejemplares similares

2321. Long-term immunogenicity of Ad26.RSV.preF/RSV preF protein vaccine against RSV in a phase 2b study by age and risk level
por: Comeaux, Christy A, et al.
Publicado: (2022)

LB14. Efficacy and Immunogenicity of an Ad26.RSV.preF-based Vaccine in the Prevention of RT-PCR-confirmed RSV-mediated Lower Respiratory Tract Disease in Adults Aged ≥65 Years: A Randomized, Placebo-controlled, Phase 2b Study
por: Falsey, Ann R, et al.
Publicado: (2021)

902. A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of a Single Immunization of Ad26.RSV.preF against RSV Infection in a Viral Challenge Model in Healthy Adults
por: DeVincenzo, John, et al.
Publicado: (2019)

Prevention of Respiratory Syncytial Virus Infection in Healthy Adults by a Single Immunization of Ad26.RSV.preF in a Human Challenge Study
por: Sadoff, Jerald, et al.
Publicado: (2021)

Vaccine-induced antibody Fc-effector functions in humans immunized with a combination Ad26.RSV.preF/RSV preF protein vaccine
por: Bartsch, Yannic C., et al.
Publicado: (2023)

2775. Safety and Immunogenicity of a Seasonal Influenza Vaccine and Ad26.RSV.preF Vaccine With and Without Co-Administration: A Randomized, Double-Blind, Placebo-Controlled Phase 2a Study in Adults Aged ≥ 60 Years
por: Comeaux, Christy, et al.
Publicado: (2019)

Combination Ad26.RSV.preF/preF protein vaccine induces superior protective immunity compared with individual vaccine components in preclinical models
por: Saeland, Eirikur, et al.
Publicado: (2023)

Phase 1/2a Safety and Immunogenicity of an Adenovirus 26 Vector Respiratory Syncytial Virus (RSV) Vaccine Encoding Prefusion F in Adults 18–50 Years and RSV-Seropositive Children 12–24 Months
por: Stuart, Arabella S V, et al.
Publicado: (2022)

1936. Efficacy of One Dose of the Respiratory Syncytial Virus (RSV) Prefusion F Protein Vaccine (RSVPreF3 OA) in Adults ≥ 60 Years of Age Persists for 2 RSV Seasons
por: Ison, Michael G, et al.
Publicado: (2023)

Is it RSV?
por: Ambrose, Christopher S.
Publicado: (2018)

Global molecular diversity of RSV – the “INFORM RSV” study
por: Langedijk, Annefleur C., et al.
Publicado: (2020)

Pre-fusion RSV F strongly boosts pre-fusion specific neutralizing responses in cattle pre-exposed to bovine RSV
por: Steff, Ann-Muriel, et al.
Publicado: (2017)

ChAd155-RSV vaccine is immunogenic and efficacious against bovine RSV infection-induced disease in young calves
por: de Jong, Rineke, et al.
Publicado: (2022)

RSV Replication, Transmission, and Disease Are Influenced by the RSV G Protein
por: Bergeron, Harrison C., et al.
Publicado: (2022)

1942. Potential Public Health Impact of Bivalent Respiratory Syncytial Virus Prefusion F (RSVpreF) Maternal Vaccine for Prevention of RSV among US Infants
por: Hanau, Ahuva, et al.
Publicado: (2023)

RSV A2-Based Prefusion F Vaccine Candidates Induce RSV A and RSV B Cross Binding and Neutralizing Antibodies and Provide Protection against RSV A and RSV B Challenge in Preclinical Models
por: Cox, Freek, et al.
Publicado: (2023)

An outbreak of RSV infections in a neonatology clinic during the RSV-season
por: Vakrilova, Liliya, et al.
Publicado: (2021)

Sequence variability of the respiratory syncytial virus (RSV) fusion gene among contemporary and historical genotypes of RSV/A and RSV/B
por: Hause, Anne M., et al.
Publicado: (2017)

LB745. Respiratory Syncytial Virus (RSV) Prefusion F Protein Candidate Vaccine (RSVPreF3 OA) is Efficacious in Adults ≥ 60 Years of Age (YOA)
por: Ison, Michael G, et al.
Publicado: (2022)

1633. Willingness to receive maternal RSV vaccine and infant monoclonal RSV antibody
por: Gidengil, Courtney, et al.
Publicado: (2023)

Correction: Sequence variability of the respiratory syncytial virus (RSV) fusion gene among contemporary and historical genotypes of RSV/A and RSV/B
por: Hause, Anne M., et al.
Publicado: (2017)

Evaluation of symptoms in respiratory syncytial virus infection in adults: psychometric evaluation of the Respiratory Infection Intensity and Impact Questionnaire™ symptom scores
por: Osborne, Richard H., et al.
Publicado: (2023)

Potential Impact of Nirsevimab on RSV Transmission and Medically Attended Lower Respiratory Tract Illness Caused by RSV: A Disease Transmission Model
por: Voirin, Nicolas, et al.
Publicado: (2021)

Emergency Department Septic Screening in Respiratory Syncytial Virus (RSV) and Non-RSV Bronchiolitis
por: Chee, Chris, et al.
Publicado: (2010)

Prevalent levels of RSV serum neutralizing antibodies in healthy adults outside the RSV-season
por: Van Der Plas, Johan L., et al.
Publicado: (2019)

Level of maternal antibodies against respiratory syncytial virus (RSV) nucleoprotein at birth and risk of RSV very severe lower respiratory tract infection
por: Receveur, Matthieu, et al.
Publicado: (2022)

Immunity to RSV in Early-Life
por: Lambert, Laura, et al.
Publicado: (2014)

Severe Rhabdomyolysis Associated With RSV
por: Bender, James, et al.
Publicado: (2017)

Nasal Microbiota in RSV Bronchiolitis
por: Schippa, Serena, et al.
Publicado: (2020)

Respiratory Syncytial Virus (RSV)
por: Walsh, Edward E., et al.
Publicado: (2015)

Socioeconomic Impact of RSV Hospitalization
por: Young, Michal, et al.
Publicado: (2021)

Immunopathology of RSV: An Updated Review
por: Bergeron, Harrison C., et al.
Publicado: (2021)

Clinical severity of RSV bronchiolitis
por: Hussain, Faris, et al.
Publicado: (2022)

Safety and Immunogenicity of a ChAd155-Vectored Respiratory Syncytial Virus (RSV) Vaccine in Healthy RSV-Seropositive Children 12–23 Months of Age
por: Díez-Domingo, Javier, et al.
Publicado: (2022)

Effects of Formalin-Inactivated Respiratory Syncytial Virus (FI-RSV) in the Perinatal Lamb Model of RSV
por: Derscheid, Rachel J., et al.
Publicado: (2013)

Bovine IgG Prevents Experimental Infection With RSV and Facilitates Human T Cell Responses to RSV
por: Nederend, Maaike, et al.
Publicado: (2020)

Characterisation of RSV Fusion Proteins from South African Patients with RSV Disease, 2019 to 2020
por: Mabilo, Prince, et al.
Publicado: (2022)

The Differences Between RSV and no RSV Acute Bronchiolitis in Hospitalized Infants: A Cross-Sectional Study
por: Christou, Evangelos, et al.
Publicado: (2022)

96. A Candidate Respiratory Syncytial Virus (RSV) Prefusion F Protein Investigational Vaccine (RSVPreF3 OA) Is Immunogenic when Administered in Adults ≥ 60 Years of Age: Results at 6 Months after Vaccination
por: Schwarz, Tino F, et al.
Publicado: (2022)

2630. Treatment of RSV Lower Respiratory Tract Infection in Two Immunocompromised Children with Polyclonal Immunoglobulin Containing Standardized Levels of Neutralizing Anti-RSV Antibody
por: Levy, Emily Ruth, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_2nu08bq8q61b2q963m10p3opko